Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04429971
Other study ID # GCO 19-2596
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 18, 2020
Est. completion date July 31, 2023

Study information

Verified date August 2023
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite an increasing armamentarium of behavioral and biomedical HIV prevention methods, since 2010 rates of new infection have remained around 40,000 annually. The demonstrated efficacy and subsequent approval of emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis (PrEP) for HIV by the FDA in 2012 was thought to represent a turning point that could significantly reduce the number of new infections. Since approval, the promise of PrEP as a transformative intervention has yet to be realized. Despite the implementation of systems for clinical evaluation for and initiation of PrEP by primary care providers, HIV specialists, and STI clinics, numerous barriers to PrEP expansion have been identified, including: 1) patient and provider lack of knowledge, 2) lack of access to medical care among high-risk individuals, 3) provider discomfort and inexperience with screening for risk behaviors, and 4) insurance and affordability. This proposal seeks to expand access to and engagement in PrEP among high risk individuals though an innovative delivery approach in the Emergency Department (ED) while addressing these four barriers.


Description:

Aim 1: Initiate a targeted ED-based PrEP screening program and optimize its feasibility and acceptability. 1. Behavioral risk factor eligibility screening will be performed using the ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool. 2. During a 3-month period, use continuous quality improvement methods to decrease the time for completion of PrEP eligibility screening to an interval that is acceptable to ED patients and providers. Aim 2: Pre-Exposure Prophylaxis Provision in the ED (PrEPPED) Trial: Identify 40 PrEP eligible patients over a 12-month period who are interested in initiating PrEP in the ED. These patients will be offered immediate PrEP (iPrEP) initiation in the ED with facilitated linkage to comprehensive out-patient care. 1. Evaluate the impact of a PrEP "starter pack" on patients agreeing to iPrEP. The primary outcome is engagement in care at 30-days post PrEP initiation visit. Secondary outcomes include retention in care, STI diagnosis, risk behavior and PrEP adherence. 2. Collect data on recruitment and attrition rates, as well as means and standard deviations for key measures that will be needed to plan a definitive trial of ED-initiated PrEP.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date July 31, 2023
Est. primary completion date July 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: PrEP screen group: - Patients 18 years of age and above - Medically stable as determined by their provider - Able to speak English - Willing and able to consent to study participation. - Not requiring hospital admission for ongoing care. iPrep group: - ED patients 18 years of age and above - HIV negative determined by 4th generation rapid testing with no evidence of acute HIV infection as determined by their ED provider - Medically stable as determined by their primary provider - Able to speak English - Able to consent to participation - Contact information available for linkage - Not requiring hospital admission for ongoing care. - Eligible for PrEP based on CDC risk behavior and clinical criteria. Exclusion Criteria: PrEP screen group: - ED patients younger than 18 years of age - Medically or psychiatrically unstable as determined by the ED provider - Unable to speak or understand English - Unable to provide consent for study participation. - Being admitted to the hospital for ongoing care iPrEP group: - ED patients younger than 18 years of age - Known HIV positive or positive rapid HIV test in ED - Medically or psychiatrically unstable as determined by the ED provider - Unable to speak or understand English - Unable to provide consent for study participation - No means of re-contact upon ED discharge - No behavioral risk factors indicating need for PrEP - Medical contraindications to PrEP - Pregnant or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Other:
PrEP screening program
ICAP Pre-Exposure Prophylaxis (PrEP) Screening for Substantial Risk and Eligibility tool
PrEP starter pack
emtricitabine/tenofovir alafenamide or emtricitabine/tenofovir disoproxil

Locations

Country Name City State
United States Mount Sinai Beth Israel Hospital New York New York

Sponsors (1)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to completion of ED PrEP screening (Implementation Component) Time to completion of screening will be calculated from the time of the patient's first contact with a health educator to the time to completion of all laboratory screening tests. 30 days post-ED visit
Primary Engagement in care (Implementation Component) Engagement is care is defined by attending at least 1 out-patient clinic appointment with a PrEP provider within 30-days of the ED visit. 30 days post-ED visit
Secondary PrEPPED Satisfaction and Acceptability Survey (RCT Component) PrEPPED Satisfaction and Acceptability Survey is a patient satisfaction questionnaire was developed by the study team. It's a series of independent Likert questions from 1-6 addressing different aspects of the program. Full scale from 0 to 18, with higher score indicating more satisfaction. 30 days post-ED visit
Secondary The VSQ-9 is a visit-specific satisfaction instrument (RCT Component) The VSQ-9 is a visit-specific satisfaction instrument adapted by the American Medical Guidelines Regimen Information Program (GRIP) survey. GRIP guide is a self-report to assess PrEP adherence at 30-days post ED visit, with 6 categorical items: excellent, very good, good, fair, poor, and very poor. 30 days post-ED visit
Secondary CDC Sexual Behavior Questions (CSBQ) (RCT Component) CDC Sexual Behavior Questions (CSBQ) to measure HIV risk behavior. CSBQ is a multi-tiered, gender-specific questionnaire developed by the Centers for Disease Control and Prevention HIV-STID Behavioral Surveillance Working Group. Three separate domains - Sexual Behavior, Drug-related HIV risk, and HIV testing. Responses are yes/no with no summation. 30 days post-ED visit
Secondary Number of new STI diagnoses (RCT Component) Number of new STI diagnosis at 30-days 30 days post-ED visit
Secondary Number of new HIV Infection (RCT Component) Number of new HIV diagnosis at 30-days 30 days post-ED visit
Secondary Visit Rating Questionnaire (VSQ9) (RCT Component) The VSQ-9 is a visit-specific satisfaction instrument adapted by the American Medical Group Association from the Visit Rating Questionnaire. Total scale from 0 to 100 with higher score indicating more satisfaction 30 days post-ED visit
See also
  Status Clinical Trial Phase
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03215901 - Life Plans Intervention Study N/A
Completed NCT03289676 - Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV Phase 1
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Active, not recruiting NCT04064567 - Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK N/A
Completed NCT04013295 - Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya N/A
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT03984136 - HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM N/A
Completed NCT02928900 - Patient Actor Training to Improve HIV Services for Adolescents in Kenya N/A
Recruiting NCT03268109 - COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
Completed NCT02797262 - Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System N/A
Completed NCT02376582 - Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS Phase 1
Completed NCT01957865 - Real-Time Antiretroviral Therapy Adherence Intervention in Uganda N/A
Completed NCT01616940 - Minority AIDS Initiative Retention and Re-Engagement Project N/A
Terminated NCT01443923 - Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV Phase 4
Completed NCT01910714 - Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth N/A
Completed NCT01084421 - A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos N/A
Completed NCT01596322 - International HIV Antiretroviral Adherence, Resistance and Survival N/A
Completed NCT03643705 - A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention N/A
Completed NCT03923231 - Pharmacokinetics of Atazanavir in Special Populations